|
1
|
Danese S and Fiocchi C: Ulcerative
colitis. N Engl J Med. 365:1713–1725. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eaden JA, Abrams KR and Mayberry JF: The
risk of colorectal cancer in ulcerative colitis: a meta-analysis.
Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cho JH and Brant SR: Recent insights into
the genetics of inflammatory bowel disease. Gastroenterology.
140:1704–1712. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thompson AI and Lees CW: Genetics of
ulcerative colitis. Inflamm Bowel Dis. 17:831–848. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slaughter DP, Southwick HW and Smejkal W:
Field cancerization in oral stratified squamous epithelium;
clinical implications of multicentric origin. Cancer. 6:963–968.
1953. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chai H and Brown RE: Field effect in
cancer-an update. Ann Clin Lab Sci. 39:331–337. 2009.PubMed/NCBI
|
|
7
|
Zimmerman NP, Vongsa RA, Wendt MK and
Dwinell MB: Chemokines and chemokine receptors in mucosal
homeostasis at the intestinal epithelial barrier in inflammatory
bowel disease. Inflamm Bowel Dis. 14:1000–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koelink PJ, Overbeek SA, Braber S, et al:
Targeting chemokine receptors in chronic inflammatory diseases: an
extensive review. Pharmacol Ther. 133:1–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williams IR: CCR6 and CCL20: partners in
intestinal immunity and lymphorganogenesis. Ann NY Acad Sci.
1072:52–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Izadpanah A, Dwinell MB, Eckmann L, et al:
Regulated MIP-3alpha/CCL20 production by human intestinal
epithelium: mechanism for modulating mucosal immunity. Am J Physiol
Gastrointest Liver Physiol. 280:G710–G719. 2001.PubMed/NCBI
|
|
11
|
Kwon JH, Keates S, Bassani L, et al:
Colonic epithelial cells are a major site of macrophage
inflammatory protein 3alpha (MIP-3alpha) production in normal colon
and inflammatory bowel disease. Gut. 51:818–826. 2002. View Article : Google Scholar
|
|
12
|
Kaser A, Ludwiczek O, Holzmann S, et al:
Increased expression of CCL20 in human inflammatory bowel disease.
J Clin Immunol. 24:74–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katchar K, Kelly CP, Keates S, et al:
MIP-3alpha neutralizing monoclonal antibody protects against
TNBS-induced colonic injury and inflammation in mice. Am J Physiol
Gastrointest Liver Physiol. 292:G1263–G1271. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cook DN, Prosser DM, Forster R, et al:
CCR6 mediates dendritic cell localization, lymphocyte homeostasis,
and immune responses in mucosal tissue. Immunity. 12:495–503. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Varona R, Cadenas V, Flores J, et al: CCR6
has a non-redundant role in the development of inflammatory bowel
disease. Eur J Immunol. 33:2937–2946. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong SC, Lo SF, Lee KC, et al: Expression
of frizzled-related protein and Wnt-signalling molecules in
invasive human breast tumours. J Pathol. 196:145–153. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Itzkowitz SH and Present DH; Crohn’s and
Colitis Foundation of America Colon Cancer in IBD Study Group.
Consensus conference: Colorectal cancer screening and surveillance
in inflammatory bowel disease. Inflamm Bowel Dis. 11:314–321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eaden JA and Mayberry JF; British Society
for Gastroenterology; Association of Coloproctology for Great
Britain and Ireland. Guidelines for screening and surveillance of
asymptomatic colorectal cancer in patients with inflammatory bowel
disease. Gut. 51(Suppl 5): V10–V12. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ullman T, Odze R and Farraye FA: Diagnosis
and management of dysplasia in patients with ulcerative colitis and
Crohn’s disease of the colon. Inflamm Bowel Dis. 15:630–638.
2009.
|
|
20
|
Velayos FS, Liu L, Lewis JD, et al:
Prevalence of colorectal cancer surveillance for ulcerative colitis
in an integrated health care delivery system. Gastroenterology.
139:1511–1518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen R, Rabinovitch PS, Crispin DA, et al:
DNA fingerprinting abnormalities can distinguish ulcerative colitis
patients with dysplasia and cancer from those who are
dysplasia/cancer-free. Am J Pathol. 162:665–672. 2003. View Article : Google Scholar
|
|
22
|
Neumann H, Vieth M, Langner C, et al:
Cancer risk in IBD: how to diagnose and how to manage DALM and ALM.
World J Gastroenterol. 17:3184–3191. 2011.PubMed/NCBI
|
|
23
|
Matsumoto T, Kudo T, Jo Y, et al:
Magnifying colonoscopy with narrow band imaging system for the
diagnosis of dysplasia in ulcerative colitis: a pilot study.
Gastrointest Endosc. 66:957–965. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Neumann H, Kiesslich R, Wallace MB and
Neurath MF: Confocal laser endomicroscopy: technical advances and
clinical applications. Gastroenterology. 139:388–392. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kiesslich R: Chromoendoscopy: what is its
true value for ulcerative colitis surveillance? Dig Dis.
28:445–451. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bista RK, Brentnall TA, Bronner MP, et al:
Using optical markers of nondysplastic rectal epithelial cells to
identify patients with ulcerative colitis-associated neoplasia.
Inflamm Bowel Dis. 17:2427–2435. 2011. View Article : Google Scholar
|
|
27
|
Ghadjar P, Rubie C, Aebersold DM and
Keilholz U: The chemokine CCL20 and its receptor CCR6 in human
malignancy with focus on colorectal cancer. Int J Cancer.
125:741–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brand S, Olszak T, Beigel F, et al: Cell
differentiation dependent expressed CCR6 mediates ERK-1/2,
SAPK/JNK, and Akt signaling resulting in proliferation and
migration of colorectal cancer cells. J Cell Biochem. 97:709–723.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rubie C, Oliveira V, Kempf K, et al:
Involvement of chemokine receptor CCR6 in colorectal cancer
metastasis. Tumour Biol. 27:166–174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Connell WR, Talbot IC, Harpaz N, et al:
Clinicopathological characteristics of colorectal carcinoma
complicating ulcerative colitis. Gut. 35:1419–1423. 1994.
View Article : Google Scholar
|
|
31
|
Hinton JM: Risk of malignant change in
ulcerative colitis. Gut. 7:427–432. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lavery IC, Chiulli RA, Jagelman DG, et al:
Survival with carcinoma arising in mucosal ulcerative colitis. Ann
Surg. 195:508–512. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mikami T, Yoshida T, Numata Y, et al:
Invasive behavior of ulcerative colitis-associated carcinoma is
related to reduced expression of CD44 extracellular domain:
comparison with sporadic colon carcinoma. Diagn Pathol. 6:302011.
View Article : Google Scholar
|
